Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis

Gut

Volumn 65, Issue 7, 2016, Pages 1230-1232

  Ehlken, Hanno ^a   Wroblewski, Raluca ^a   Corpechot, Christophe ^b   Arrivé, Lionel ^b,c   Lezius, Susanne ^a   Hartl, Johannes ^a   Denzer, Ulrike W ^a   Lohse, Ansgar W ^b   Chazouilleres, Olivier ^a   Schramm, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE DUCT CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DIAGNOSTIC ACCURACY; FOLLOW UP; GALLBLADDER CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; LETTER; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPLEEN SIZE; ULTRASOUND; BILIARY CIRRHOSIS; SCLEROSING CHOLANGITIS; SPLEEN;

CHOLANGITIS, SCLEROSING; HUMANS; LIVER CIRRHOSIS, BILIARY; SPLEEN;

EID: 84960172142     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311452     Document Type: Letter

References (7)

1. van der Meer AJ, Hansen BE, Fattovich G, et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut 2015;64:322-31.
2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
3. Ponsioen CY, Chapman RW, Chazouillères O, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis; review and results from an International PSC Study Group consensus process. Hepatology Published Online First: 29 Sep 2015. doi:10.1002/hep.28256
4. Corpechot C, Gaouar F, Naggar El A, et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology 2014;146:970-9; quize15-6.
5. Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010;59:861-6.
6. Tapper EB, Cohen EB, Patel K, et al. Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2012;10:932-937.
7. Ehlken H, Lohse AW, Schramm C. Transient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations. Gastroenterology 2014;147:542-3.